Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

• Hauptverfasser: Eugenia Oviedo-Joekes (Verfasst von), Sophia Dobischok (Verfasst von), José Carvajal (Verfasst von), Scott MacDonald (Verfasst von), Cheryl McDermid (Verfasst von), Piotr Klakowicz (Verfasst von), Scott Harrison (Verfasst von), Julie LaJeunesse (Verfasst von), Nancy Chow (Verfasst von), Murray Brown (Verfasst von), Sam Gill (Verfasst von), Martin Schechter (Verfasst von)
• Format: Buch
• Veröffentlicht: BMC, 2023-05-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background To support public health measures during the COVID-19 pandemic, oral opioid agonist treatment (OAT) take-home doses were expanded in Western countries with positive results. Injectable OAT (iOAT) take-home doses were previously not an eligible option, and were made available for...